回到顶部
2025-01-02当前位置:网站首页 > 行业动态 > 数据共享 > 期刊杂志 >

恩度联合化疗对Ⅳ期非小细胞肺癌患者临床疗效与肿瘤标志物的影响

  [摘要] 目的 探討恩度联合化疗一线治疗Ⅳ期非小细胞肺癌的临床疗效及血清肿瘤标志物的变化。方法 方便选取阳谷县人民医院肿瘤血液内科(2015年1月—2017年1月)诊疗的80例Ⅳ期非小细胞肺癌患者作为研究对象,采用随机的方法分成两组,40例的对照组患者采用的是化疗,40例的观察组患者在对照组基础上给予恩度治疗,对比两组患者临床疗效和疾病无进展生存期以及治疗前后血清肿瘤标志物水平。结果 两组患者临床疗效分别为57.50% vs 30.00%,观察组有效率显著高于对照组患者(χ2=15.365 1,P, 百拇医药
 [关键词] 恩度;化疗;一线治疗;Ⅳ期非小细胞肺癌;临床疗效;肿瘤标志物

 [中图分类号] R734.2 [文献标识码] A [文章编号] 1674-0742(2019)09(a)-0022-03

 [Abstract] Objective To investigate the clinical efficacy and serum tumor markers of patients with stage IV non-small cell lung cancer treated with Endotherapy combined with chemotherapy. Methods Convenient select eighty patients with stage IV non-small cell lung cancer who were treated by Department of Oncology and Blood Medicine of Yanggu County People's Hospital (January 2015 to January 2017) were enrolled in the study. They were randomly divided into two groups and 40 patients in the control group, chemotherapy was used, and 40 patients in the observation group were treated with endotherapy on the basis of the control group. The clinical efficacy and disease progression-free survival and serum tumor marker levels before and after treatment were compared between the two groups. Results The clinical efficacy of the two groups was 57.50% vs 30.00%, and the effective rate of the observation group was significantly higher than that of the control group (χ2=15.365 1, P, 百拇医药(李江) 第 1 2 3 页 下一页
 百拇医药网 http://www.100md.com/html/paper/1674-0742/2019/25/07.htm
上一篇:UGT1A1基因突变对乙型肝炎慢加亚急性肝衰竭患者转归的影响
下一篇:腰椎管内骨性占位经皮脊柱内镜治疗分析(论著)
Copyright © 2012-2024. All rights reserved  备案号:京ICP备06040839号-8  XML地图  模板巴巴
行业动态 | 生活保健 | 中医中药 | 美容天地

扫码关注公众号